Variables | Pegloticase | Pegloticase | Placebo |
---|---|---|---|
 | biweekly | monthly |  |
(n= 62) | (n= 64) | (n= 29) | |
Week 13 | |||
 Patients with evaluable tophi at visit, n | 46 | 48 | 25 |
 CR, n (%) | 10 (22) | 4 (8) | 0 |
 P valueb | 0.011 | 0.292 | – |
Week 25 | |||
 Patients with evaluable tophi at visit, n | 40 | 39 | 24 |
 CR, n (%) | 18 (45) | 10 (26) | 2 (8) |
 P valueb | 0.002 | 0.110 | – |
Final visitc | |||
 Patients with evaluable tophi, n | 52 | 52 | 27 |
 CR, n (%) | 21 (40) | 11 (21) | 2 (7) |
 P valueb | 0.002 | 0.200 | – |